GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lexagene Holdings Inc (OTCPK:LXXGQ) » Definitions » Price-to-Owner-Earnings

Lexagene Holdings (Lexagene Holdings) Price-to-Owner-Earnings : (As of Jun. 04, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Lexagene Holdings Price-to-Owner-Earnings?

As of today (2024-06-04), Lexagene Holdings's share price is $0.0806. Lexagene Holdings does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Lexagene Holdings's Price-to-Owner-Earnings or its related term are showing as below:


LXXGQ's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 32.295
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-04), Lexagene Holdings's share price is $0.0806. Lexagene Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Nov. 2022 was $-0.07. Therefore, Lexagene Holdings's PE Ratio for today is At Loss.

As of today (2024-06-04), Lexagene Holdings's share price is $0.0806. Lexagene Holdings's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.07. Therefore, Lexagene Holdings's PE Ratio without NRI for today is At Loss.


Lexagene Holdings Price-to-Owner-Earnings Historical Data

The historical data trend for Lexagene Holdings's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexagene Holdings Price-to-Owner-Earnings Chart

Lexagene Holdings Annual Data
Trend Mar13 Mar14 Mar15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lexagene Holdings Quarterly Data
Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lexagene Holdings's Price-to-Owner-Earnings

For the Medical Devices subindustry, Lexagene Holdings's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexagene Holdings's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lexagene Holdings's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Lexagene Holdings's Price-to-Owner-Earnings falls into.



Lexagene Holdings Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Lexagene Holdings's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.0806/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lexagene Holdings  (OTCPK:LXXGQ) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Lexagene Holdings Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Lexagene Holdings's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexagene Holdings (Lexagene Holdings) Business Description

Traded in Other Exchanges
N/A
Address
500 Cummings Center, Suite 4550, Beverly, MA, USA, 01915
Lexagene Holdings Inc is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The MiQLab system delivers sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.